Analyst Mitchell Kapoor from H.C. Wainwright reiterated a Buy rating on Instil Bio (TIL – Research Report) and keeping the price target at $110.00.
Mitchell Kapoor has given his Buy rating due to a combination of factors, primarily focusing on the promising developments in Instil Bio’s pipeline. The company is set to release significant data from its AXN-2510 program, which targets non-small cell lung cancer (NSCLC) in collaboration with its partner, ImmuneOnco. This includes data from both monotherapy and combination therapy trials in China, with expectations for further trials in the U.S. by the end of 2025.
Kapoor highlights the potential impact of these developments on Instil Bio’s stock, drawing parallels to the market’s positive response to similar data from Summit Therapeutics. The anticipated data releases are seen as pivotal, providing guidance on the U.S. market opportunity and potentially driving substantial stock appreciation. Furthermore, Kapoor notes the competitive landscape, suggesting that Instil Bio’s approach could carve out a significant niche in the evolving field of cancer therapies, particularly in checkpoint inhibition and anti-angiogenesis strategies.
Kapoor covers the Healthcare sector, focusing on stocks such as Halozyme, Sarepta Therapeutics, and Summit Therapeutics. According to TipRanks, Kapoor has an average return of -21.9% and a 26.75% success rate on recommended stocks.